查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1630996

美国口服固态剂型契约製造市场：市场规模、份额及趋势分析（按产品、机制、最终用途、国家及细分市场，2025-2030 年）

U.S. Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Mechanism (Immediate Release, Delayed Release), By End Use, By Country And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

美国固态口服剂型契约製造市场的成长与趋势：

根据 Grand View Research, Inc. 的一份新报告，美国口服固态剂量契约製造市场规模预计到 2030 年将达到 164.3 亿美元，2025 年至 2030 年的复合年增长率为 6.1%。该市场的成长得益于该国医药外包的增加和技术进步等因素。以患者为中心的剂型的需求随着时间的推移而增加，并且由于其提高了药物依从性，已成为医疗保健领域的一个重要趋势。因此，製造商正在生产优先考虑易于吞嚥的口服剂型。

为了使固态口服药物更容易获得，製药赞助商正在创新地将药物製成微型或迷你片剂或喷雾胶囊。这种配方方法越来越受欢迎，尤其是在儿童和老年人中。慢性病和感染疾病的日益普及也是推动新型疗法需求的一个主要因素。此外，老年人口的不断增长导致慢性病发病率上升，进一步推动了对新治疗过程的需求。

现有药物的不良反应也增加了对新治疗方法的需求。例如，根据利物浦大学 2022 年 7 月发表的一项研究，因副作用相关的住院率从 2004 年的 6.5% 上升到 2019 年的 16.5%。对现有治疗产生不良反应的病例不断增加，预计将推动未来对新治疗的需求。

创新和临床速度是许多生物製药公司的关键因素。小型公司和专业生物製药公司越来越依赖满足产业内的这些关键要求。许多 CRO 和 CDMO 都将自己定位为「一站式服务公司」。一站式服务是一种服务模式，其中 CRO 负责处理从原料药到配方、从早期开发到商业化的所有事务。为了提供此类服务，CDMO 必须拥有广泛的实行技术和专业能力来解决特定的问题。

此外，主要企业日益增多的策略性倡议也有望推动美国口服固态剂量 (OSD)契约製造市场的成长。例如，2023年1月，Catalent与Ethicann达成合作，利用Catalent的Zydis口溶锭(ODT)技术开发Ethicann的临床药物管线。再例如，2023年3月，龙沙宣布在其菲斯普工厂全面运作新的临床和商业药品製造生产线。此次扩张预计将增强该公司的药物输送服务（DPS）。

美国口服固态製剂契约製造市场：概览

  • 根据产品类型，锭剂领域在 2024 年占据最高的市场占有率。这是因为锭剂广泛可用、易于生产且患者接受度高。
  • 预计未来几年胶囊市场将出现显着成长。在一个胶囊中配製具有不同释放特性的多种药理成分的能力推动了其需求。
  • 基于机制，控释将在 2024 年占据市场主导地位。控释机制具有多种优势，包括提高功效和安全性、减少给药频率和稳定血中浓度。
  • 根据最终用途，大型企业部门将在 2024 年占据市场主导地位。契约製造製造商通常能够根据需求波动增加或减少生产量。对于面临 OSD 产品需求波动的大型製药企业来说，这种弹性是一种优势。
  • 预计未来几年小型企业将以显着的成长速度发展。中小企业的资金资源往往有限。拥有自己的製造工厂的建设和运营成本可能太高。合约製造可为您提供最先进的生产能力，且无需大量的前期投资。

目录

第一章 分析方法及范围

第 2 章执行摘要

第 3 章美国口服固态剂型契约製造市场：驱动因素、趋势与范围

  • 市场联动展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 商业环境分析
    • 产业分析：波特五力分析
    • PESTLE分析

第 4 章美国口服固态剂型契约製造市场：按产品分類的业务分析

  • 按产品市场占有率（2024 年和 2030 年）
  • 产品仪表板
  • 依产品分類的市场规模预测及趋势分析（2018-2030）
  • 锭剂
  • 胶囊
  • 粉末
  • 颗粒
  • 其他的

第 5 章美国口服固态剂型契约製造市场：按机制分類的业务分析

  • 按机制分類的市场占有率（2024 年和 2030 年）
  • 机制仪表板
  • 依机制分類的市场规模预测及趋势分析（2018-2030）
  • 即时发布
  • 延迟释放
  • 控释

第六章美国口服固态剂型契约製造市场：依最终用途分類的业务分析

  • 按最终用途分類的市场占有率（2024 年和 2030 年）
  • 最终用途仪表板
  • 按最终用途分類的市场规模预测和趋势分析（2018-2030 年）
  • 大型企业
  • 中小型企业
  • 其他的

第七章 竞争格局

  • 市场参与企业概况
  • 公司市场地位分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Catalent, Inc（Novo Holdings A/S）
    • Lonza
    • AbbVie Inc.
    • Aenova Group
    • Adare Pharma Solutions
    • Boehringer Ingelheim International GmbH
    • Jubilant Pharmova Limited
    • Patheon Pharma Services（Thermo Fisher Scientific Inc.）
    • Recipharm AB
    • CordenPharma
    • Siegfried Holding AG
Product Code: GVR-4-68040-122-8

U.S. Oral Solid Dosage Contract Manufacturing Market Growth & Trends:

The U.S. oral solid dosage contract manufacturing market size is expected to reach USD 16.43 billion by 2030, registering a CAGR of 6.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to factors such as the increasing pharmaceutical outsourcing and technological advancements in the country. The demand for patient-centric dosage forms has been increasing with time, making it a pivotal trend in the medical field, as it enhances medication adherence. Consequently, manufacturers are producing oral dosage forms that prioritize ease of swallowing.

To render solid oral drugs more user-friendly, drug sponsors are innovatively transforming drugs into micro or mini tablets and sprinkle capsules. This formulation approach is gaining popularity, especially among the pediatric and geriatric populations. The growing prevalence of chronic and infectious diseases is one of the major factors responsible for the rising demand for novel therapies. Furthermore, the growing geriatric population is contributing to the rising incidence of chronic diseases, further supporting the demand for novel treatment processes.

Adverse drug reactions to existing drugs are also contributing to the demand for novel treatment options. For instance, in July 2022, research published by the University of Liverpool stated that adverse drug reaction-related hospital admissions increased from 6.5% in 2004 to 16.5% in 2019. A rise in the number of cases involving adverse drug reactions to existing therapies is expected to boost the demand for new therapies in the future.

For many biopharmaceutical companies, innovations and speed-to-clinic factors are of critical importance. Small companies and specialty biopharmaceutical players increasingly rely upon delivering these important requirements within the industry. Many CROs and CDMOs promote themselves as one-stop-shop companies. The one-stop-shop service model is where a CRO handles everything from API to dosage form and early development to commercialization. To provide these services, a CDMO must have a wide range of enabling technologies and specialized handling capabilities to address specific problem statements.

Furthermore, increasing undertaking of strategic initiatives by key players is also expected to drive U.S. oral solid dosage (OSD) contract manufacturing market growth. For instance, in January 2023, Catalent and Ethicann collaborated to develop Ethicann's clinical drug pipeline using Catalent's orally disintegrating tablet (ODT) technology 'Zydis'. In another instance, in March 2023, Lonza announced that its new clinical and commercial drug product manufacturing line at its Visp site had become fully operational. The expansion is expected to strengthen the company's Drug Product Services (DPS) offering.

U.S. Oral Solid Dosage Contract Manufacturing Market Report Highlights:

  • Based on product type, the tablets segment captured the highest market share in 2024.This is attributed to their widespread use, ease of manufacturing, and strong patient acceptance rate.
  • The capsule segment is expected to show significant market growth in the coming years. Multiple pharmacological ingredients with various release characteristics can be combined in capsules, thus driving their demand.
  • Based on the mechanism, the controlled release segment dominated the market in 2024. The controlled release mechanism offers multiple advantages, such as improved efficacy and safety, reduced dosage frequency, and steady blood levels.
  • Based on the end-user, the large companies segment dominated the market in 2024. Contract manufacturers generally have the capacity to scale production up or down based on requirement fluctuation. This flexibility can be advantageous for large pharma companies that experience varying levels of demand for their OSD products.
  • Medium- and small-sized companies are expected to advance at a significant growth rate in the coming years. Financial resources are frequently limited for small- and medium-sized companies. Their own manufacturing facilities might be too expensive to build and operate. They can gain cutting-edge production capabilities through contract manufacturing without making a large initial investment.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Mechanism
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Oral Solid Dosage Contract Manufacturing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. U.S. Oral Solid Dosage Contract Manufacturing Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Tablets
    • 4.4.1. Tablets Market, 2018 - 2030 (USD Million)
  • 4.5. Capsules
    • 4.5.1. Capsules Market, 2018 - 2030 (USD Million)
  • 4.6. Powders
    • 4.6.1. Powders Market, 2018 - 2030 (USD Million)
  • 4.7. Granules
    • 4.7.1. Granules Market, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Oral Solid Dosage Contract Manufacturing Market: Mechanism Business Analysis

  • 5.1. Mechanism Market Share, 2024 & 2030
  • 5.2. Mechanism Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Mechanism, 2018 to 2030 (USD Million)
  • 5.4. Immediate Release
    • 5.4.1. Immediate Release Market, 2018 - 2030 (USD Million)
  • 5.5. Delayed Release
    • 5.5.1. Delayed Release Market, 2018 - 2030 (USD Million)
  • 5.6. Controlled Release
    • 5.6.1. Controlled Release Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Oral Solid Dosage Contract Manufacturing Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Large Size Companies
    • 6.4.1. Large Size Companies Market, 2018 - 2030 (USD Million)
  • 6.5. Medium & Small Size Companies
    • 6.5.1. Medium & Small Size Companies Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Catalent, Inc (Novo Holdings A/S)
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Lonza
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. AbbVie Inc.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Aenova Group
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Adare Pharma Solutions
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Boehringer Ingelheim International GmbH
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Jubilant Pharmova Limited
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Patheon Pharma Services (Thermo Fisher Scientific Inc.)
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Recipharm AB
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. CordenPharma
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Siegfried Holding AG
      • 7.5.11.1. Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Product Benchmarking
      • 7.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. oral solid dosage contract manufacturing market, by region, 2018 - 2030 (USD Million)
  • Table 4 U.S. oral solid dosage contract manufacturing market, by product, 2018 - 2030 (USD Million)
  • Table 5 U.S. oral solid dosage contract manufacturing market, by mechanism, 2018 - 2030 (USD Million)
  • Table 6 U.S. oral solid dosage contract manufacturing market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 U.S. oral solid dosage contract manufacturing market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product and mechanism outlook (USD Million)
  • Fig. 10 End use outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 U.S. oral solid dosage contract manufacturing market dynamics
  • Fig. 13 U.S. oral solid dosage contract manufacturing market: Porter's five forces analysis
  • Fig. 14 U.S. oral solid dosage contract manufacturing market: PESTLE analysis
  • Fig. 15 U.S. oral solid dosage contract manufacturing market: Product segment dashboard
  • Fig. 16 U.S. oral solid dosage contract manufacturing market: Product market share analysis, 2024 & 2030
  • Fig. 17 Tablets market, 2018 - 2030 (USD Million)
  • Fig. 18 Capsules market, 2018 - 2030 (USD Million)
  • Fig. 19 Powders market, 2018 - 2030 (USD Million)
  • Fig. 20 Granules market, 2018 - 2030 (USD Million)
  • Fig. 21 Others market, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. oral solid dosage contract manufacturing market: Mechanism segment dashboard
  • Fig. 23 U.S. oral solid dosage contract manufacturing market: Mechanism market share analysis, 2024 & 2030
  • Fig. 24 Immediate release market, 2018 - 2030 (USD Million)
  • Fig. 25 Delayed release market, 2018 - 2030 (USD Million)
  • Fig. 26 Controlled release market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. oral solid dosage contract manufacturing market: End use segment dashboard
  • Fig. 28 U.S. oral solid dosage contract manufacturing market: End use market share analysis, 2024 & 2030
  • Fig. 29 Large size companies market, 2018 - 2030 (USD Million)
  • Fig. 30 Medium & small size companies market, 2018 - 2030 (USD Million)
  • Fig. 31 Others market, 2018 - 2030 (USD Million)
  • Fig. 32 Company categorization
  • Fig. 33 Company market position analysis
  • Fig. 34 Strategic framework